Company Summary: Organogenesis Holdings Inc.

Overview

Organogenesis Holdings Inc. is a publicly traded biotechnology and medical device company specializing in the development, manufacturing, and commercialization of regenerative medicine products. Its primary focus is on advanced wound care, surgical tissue regeneration, and other biopharmaceutical applications.

Key Operations and Focus Areas

• Product Portfolio: The company produces tissue-based regenerative products, including skin substitutes used for wound healing and tissue repair.
• Market Segments: Focuses on sectors such as chronic and acute wounds, burns, surgical and procedural applications.
• Regulatory Approvals: Its products include allogeneic stem cell therapies and other tissue regeneration solutions that are often FDA-approved or cleared for specific medical uses.

Company Details

• Number of Employees: The exact number of employees is not explicitly stated in the provided text.
• Number of Customers: Specific customer counts are not provided.
• Revenue: Not specifically disclosed in the provided excerpt.
• Net Income: Not disclosed; the financial data such as income or profit figures are not included in the given text.

Stock and Market Information

• Stock Symbol: ORGO (traded on Nasdaq Capital Market)
• Market Capitalization: Approximately $199.9 million as of June 30, 2024, based on the closing sale price of its Class A common stock.
• Outstanding Shares: As of April 28, 2025, there were 126,853,536 shares of its Class A common stock outstanding.

Business Model and Strategy

• The company has a significant focus on research and development within regenerative medicine.
• It relies on a combination of product sales and strategic partnerships, secured through regulatory approval pathways.
• The company emphasizes long-term growth through continuous innovation and expanding its product pipeline.

Additional Notes

• The company is under the oversight of multiple corporate governance and compliance policies, including confidentiality, insider trading, and related-party transaction policies.
• The firm has a history of executive compensation tied closely to company performance, with stock options and equity awards aligning leadership interests with long-term stockholder value.

Note: Specific financial figures like revenue and net income are not provided in the given filer excerpt.